No analyst coverage available for this stock.
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceutical, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis; FB825, which is in Phase IIa clinical trial for treating atopic dermatitis, allergic diseases, and asthma; and FB918, an antibody targeting the interleukin 33 that is in pre-clinical stage for the treatment of asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and sale of agricultural products. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.